×
About 1,305 results

ALLMedicine™ Zollinger-Ellison Syndrome Center

Research & Reviews  69 results

Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis...
https://doi.org/10.14309/ajg.0000000000001487
The American Journal of Gastroenterology; Bhattacharya S, Blau JE et. al.

Sep 14th, 2021 - Zollinger-Ellison syndrome (ZES) is characterized by gastrinoma-induced hypergastrinemia causing excessive gastric acid secretion. Secretin stimulation tests (SSTs) are required for diagnosis in the majority of patients. Two case reports suggest t...

Successful endoscopic resection of an unusually enlarged and pedunculated type I gastri...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378368
BMJ Case Reports; Odisho T, Shi D et. al.

Aug 21st, 2021 - Three distinct gastric carcinoid (GC) tumour types have been described based on differing biological behaviour and prognoses. Type I GC tumours account for the vast majority (70%-80%), are associated with chronic atrophic gastritis and have a low ...

Total gastrectomy for severe proton pump inhibitor-induced hypomagnesemia in a MEN1/Zol...
https://doi.org/10.1016/j.pan.2020.12.002
Pancreatology : Official Journal of the International Ass... Perrier M, Delemer B et. al.

Dec 15th, 2020 - We report here the first case of life-threatening hypomagnesemia in a Zollinger-Ellison syndrome patient with multiple endocrine neoplasia type 1 (MEN1) syndrome. The severe symptomatic hypomagnesemia proved to be due to proton pump inhibitors (PP...

Primary intracardiac gastrinoma causing Zollinger-Ellison syndrome.
https://doi.org/10.1093/eurheartj/ehaa512
European Heart Journal; Luiso D, Zuccarino F et. al.

Jul 18th, 2020 - Primary intracardiac gastrinoma causing Zollinger-Ellison syndrome.|2020|Luiso D,Zuccarino F,Tizón-Marcos H,Ble M,|

Jejunal Perforations in Zollinger-Ellison Syndrome: Expect the Unexpected.
https://www.ncbi.nlm.nih.gov/pubmed/32106911
The American Surgeon; Freund MR, Reissman P et. al.

Feb 29th, 2020 - Jejunal Perforations in Zollinger-Ellison Syndrome: Expect the Unexpected.|2020|Freund MR,Reissman P,Schwarz AD,|etiology,etiology,etiology,complications,

see more →

Drugs  434 results see all →

News  18 results

Appco Pharma LLC Issues Voluntary Nationwide Recall of Ranitidine Hydrochloride Capsules 150 mg and 300 mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) | FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/appco-pharma-llc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-capsules-150-mg-and-300

Summary Company Announcement Date: January 07, 2020 FDA Publish Date: January 07, 2020 Product Type: Drugs Reason for Announcement: Recall Reason Description NDMA (Nitrosodimethylamine) impurity Company Name: Appco Pharma LLC Brand Name: Brand Nam...

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Pantoprazole Sodium for Injection 40 Mg Per Vial, Due to Presence of Glass Particles in the Vial | FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/auromedics-pharma-llc-issues-voluntary-nationwide-recall-pantoprazole-sodium-injection-40-mg-vial

Summary Company Announcement Date: December 19, 2017 FDA Publish Date: December 29, 2017 Product Type: Drugs Generic Drugs Reason for Announcement: Recall Reason Description Contains glass particles Company Name: AuroMedics Pharma LLC Brand Name: ...

Continue, Stop, or Taper the PPI?
https://www.medscape.com/viewarticle/920314_2

Oct 25th, 2019 - My Take: It's Time for a Change. Do You Agree? The patient may not like it, but it's worth at least trying to taper his PPI at this time, with a goal of stopping regular PPI dosing altogether. Like many others, this patient is using his PPI as chr...

Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to An Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product | FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-elevated

Summary Company Announcement Date: September 23, 2019 FDA Publish Date: September 23, 2019 Product Type: Drugs Reason for Announcement: Recall Reason Description Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) Compa...

Improper Proton Pump Inhibitor Prescriptions Criticized
https://www.staging.medscape.com/viewarticle/913377

May 22nd, 2019 - SAN DIEGO — Prescriptions for proton pump inhibitors (PPIs) have skyrocketed over the past 2 decades, along with concerns about inappropriate use and adverse events. Prescriptions for PPIs went from 1.6% of ambulatory care visits in 1998 to 7.6% i...

see more →

Patient Education  1 results see all →